Current Environment:

 

In applying precision medicine to vaccinology, the PVP employs several emerging concepts, approaches, and technologies that accelerate and de-risk development of vaccines tailored for distinct populations:

  • Human in vitro modeling
  • Systems biology
  • Use of big data/global molecular/OMIC approaches to characterize molecular signatures for vaccine correlates of protection
  • Discovery and development of adjuvants, small molecules ​and other bioactives that can boost immune responses in a population specific manner​​​​
  • We are currently working on vaccines against:
    • SARS-CoV-2
    • Human Immunodeficiency Virus (HIV)
    • Respiratory SyncytialVirus (RSV)
    • Influenza
    • Pertussis (whooping cough)
    • Opioid vaccines to prevent overdose
Discovery and development of precision vaccines may include a series of sequential approaches including system biology analysis of biosamples from clinical trials to define vaccine-induced cellular and molecular signatures that correlate with immunogenicity, thereby generating new mechanistic hypotheses; use of human in vitro systems for hypothesis testing and targeted adjuvant discovery employing population-specific biosamples, selection of appropriate animal models and clinical trials in specific vulnerable populations.